Cargando…
Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy
BACKGROUND: The majority of patients with idiopathic pulmonary arterial hypertension (IPAH) in functional classes II and III are currently being treated with non-parenteral therapies, including endothelin receptor antagonists (ERA), phosphodiesterase (PDE)-5 inhibitors, inhaled iloprost or combinati...
Autores principales: | Knudsen, Lars, Schurawlew, Alexander, Nickel, Nils, Tiede, Henning, Ghofrani, Hossein A, Wilkens, Heinrike, Ewert, Ralf, Halank, Michael, Klose, Hans, Bäzner, Carlos, Behr, Jürgen, Hoeper, Marius M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247176/ https://www.ncbi.nlm.nih.gov/pubmed/22133492 http://dx.doi.org/10.1186/1471-2466-11-56 |
Ejemplares similares
-
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis
por: Schmidt, Kai-Helge, et al.
Publicado: (2023) -
Outcome of painful bone marrow edema of the femoral head following treatment with parenteral iloprost
por: Meizer, Roland, et al.
Publicado: (2009) -
Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009) -
Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study
por: Gall, Henning, et al.
Publicado: (2016) -
Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)